A Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors (Retroviral

Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors (Retroviral, Adenoviral, Lentiviral, Adeno-Associated, Others), Plasmid DNA, Non-viral, Lipid/polymer, Electroporation, Nanoparticles, and Others),  By Grade (GMP Grade and R&D Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics, and Marketed Therapeutics) By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

A plasmid is a small, extrachromosomal DNA molecule within a cell that is physically separated from chromosomal DNA and can replicate independently. The use of plasmid DNA (pDNA) is gaining traction in the research community nowadays for its usage in clinical research applications, genetic immunization, and gene therapy. pDNA is becoming increasingly useful in production of DNA vaccines and gene medicines. It can be directly used as a therapeutic agent or indirectly used for various applications such as a starting material for transient transfection to produce transient proteins and viral vector constructs. The advantage of using pDNA in genetic therapies is that no major formulation or alteration of plasmid molecules is required. Approximately, half of the plasmid encodes the two major elements used by bacteria during production, which are bacterial origin of replication and a selectable marker. The other half of the plasmid comprises of a complete eukaryotic expression element, consisting of a promoter, a region encoding the gene of interest, and a termination sequence.
Market Dynamics
Key players operating in the global plasmid DNA manufacturing market are focusing on the adoption of inorganic growth strategies such as agreements, this is expected to drive the market growth during the forecast period. For instance, in January 2019, Aldevron announced an agreement with Oxford Genetics to bring a standardized range of its plasmids for lentiviral manufacturing into the market. Under this agreement, Aldevron offered Rev, VSV-G, and expression plasmids for various applications. Furthermore, in January 2021, Genscript Biotech Corporation entered into a strategic partnership agreement with Genopis, Inc., for the manufacturing service of GMP Plasmids. With this, both the companies established a revenue-sharing agreement for the promotion, selling, and production of GMP plasmids globally.
Key features of the study:
This report provides in-depth analysis of the global plasmid DNA manufacturing market, and provides market size (us$ mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
it elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Global Plasmid DNA Manufacturing Market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Cobra Biologics and Pharmaceutical Services*, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, Waisman Biomanufacturing, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, Genscript Biotech Corporation, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., Cepham Life Sciences, Delphi Genetics, Biomiga, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd, Luina Bio Pty Ltd, Ajinomoto Bio-Pharma Services, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., and Geneone Life Science
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Global Plasmid DNA Manufacturing Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Plasmid DNA Manufacturing Market.
Detailed Segmentation:
Global Plasmid DNA Manufacturing Market, By Product Type:
Viral Vectors
Retroviral
Adenoviral
Lentiviral
Adeno-Associated
Others
Plasmid DNA
Non-viral
Lipid/polymer
Electroporation
Nanoparticles
Others
Global Plasmid DNA Manufacturing Market, By Grade:
GMP Grade
R&D Grade
Global Plasmid DNA Manufacturing Market, By Application:
DNA Vaccines
Gene Therapy
Immunotherapy
Others
Global Plasmid DNA Manufacturing Market, By Development Phase:
Pre-Clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
Global Plasmid DNA Manufacturing Market, By Region:
North America
By Product Type
Viral Vectors
Retroviral
Adenoviral
Lentiviral
Adeno-Associated
Others
Plasmid DNA
Non-viral
Lipid/polymer
Electroporation
Nanoparticles
Others
By Grade
GMP Grade
R&D Grade
By Application
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Development Phase
Pre-Clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
By Country
U.S.
Canada
Latin America
By Product Type
Viral Vectors
Retroviral
Adenoviral
Lentiviral
Adeno-Associated
Others
Plasmid DNA
Non-viral
Lipid/polymer
Electroporation
Nanoparticles
Others
By Grade
GMP Grade
R&D Grade
By Application
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Development Phase
Pre-Clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type
Viral Vectors
Retroviral
Adenoviral
Lentiviral
Adeno-Associated
Others
Plasmid DNA
Non-viral
Lipid/polymer
Electroporation
Nanoparticles
Others
By Grade
GMP Grade
R&D Grade
By Application
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Development Phase
Pre-Clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type
Viral Vectors
Retroviral
Adenoviral
Lentiviral
Adeno-Associated
Others
Plasmid DNA
Non-viral
Lipid/polymer
Electroporation
Nanoparticles
Others
By Grade
GMP Grade
R&D Grade
By Application
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Development Phase
Pre-Clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type
Viral Vectors
Retroviral
Adenoviral
Lentiviral
Adeno-Associated
Others
Plasmid DNA
Non-viral
Lipid/polymer
Electroporation
Nanoparticles
Others
By Grade
GMP Grade
R&D Grade
By Application
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Development Phase
Pre-Clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
By Country
GCC
Israel
Rest of Middle East
Africa
By Product Type
Viral Vectors
Retroviral
Adenoviral
Lentiviral
Adeno-Associated
Others
Plasmid DNA
Non-viral
Lipid/polymer
Electroporation
Nanoparticles
Others
By Grade
GMP Grade
R&D Grade
By Application
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Development Phase
Pre-Clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
By Country
South Africa
Central Africa
North Africa
Company Profiles
Cobra Biologics and Pharmaceutical Services*
Company Highlights
Drug Class Portfolio
Key Highlights
Financial Performance
Strategies
VGXI, Inc.
Aldevron
Kaneka Corporation
Nature Technology Corporation
PlasmidFactory GmbH & Co. KG
Cell and Gene Therapy Catapult
Waisman Biomanufacturing
LakePharma, Inc.
MeiraGTx Limited
Eurofins Genomics
Vigene Biosciences
Luminous BioSciences (LBS), LLC
Genscript Biotech Corporation
GENEWIZ
Creative Biogene
Akron Biotech
Biomay
JAFRAL Ltd.,
Cepham Life Sciences
Delphi Genetics
Biomiga
GeneImmune Biotechnology Corp.
Lonza
Greenpak Biotech Ltd
Luina Bio Pty Ltd
Ajinomoto Bio-Pharma Services
Synbio Technologies
Genopis Inc.
Altogen Biosystems
Puresyn, Inc.
Geneone Life Science
“*” marked represents similar segmentation in other categories in the respective section.